CompletedPhase 1

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

United States62 participantsStarted 2018-05-01

Plain-language summary

This research study is studying an investigational combination of drugs as a possible treatment for advanced solid tumors: melanoma, ovarian, renal, or colorectal cancer. The drugs involved in this study are: * Pembrolizumab * AMG386

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓-Serum creatinine OR Measured or ≤1.5 X upper limit of normal (ULN) OR calculateda creatinine clearance ≥60 mL/min for subject with creatinine levels (GFR can also be used in place of \> 1.5 X institutional ULN creatinine or CrCl)

What they're measuring

Number of Participants Experienced Dose Limit Toxicities (DLT)

Timeframe: 3 weeks

Maximum Tolerated Dose (MTD) of Trebananib

Timeframe: 3 weeks

Grade 3 or Higher Toxicity Rate in Expansion Cohort

Timeframe: The median follow up time was 3.3 months (range: 0.6 to 25.3 months).

Trial details

NCT IDNCT03239145

SponsorDana-Farber Cancer Institute

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-13

Results submitted2026-01-09

View on ClinicalTrials.gov More Advanced Solid Tumor trials